Iovance's lifileucel plus pembrolizumab shows 62.5% ORR in frontline advanced melanoma

Iovance's Phase 2 trial of lifileucel plus pembrolizumab delivered a 62.5% objective response rate and 29.2% complete response rate in frontline advanced melanoma, with median overall survival not yet reached at 50.9 months.

Detected & updated continuously · Source: Nebula